Heparinized peripheral blood was collected from healthy volunteers for the mixed lymphocyte reaction (MLR), mixed DC-lymphocyte reaction (MDCLR), and the interleukin (IL) 2 MLR and IL 2 MDCLR assays.
Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in breast ...
Two key poster presentations to highlight cTRLs as a novel cell type well-equipped to overcome the challenges of traditional cell therapies in solid tumors, like colorectal cancer and melanoma cTRL's ...
In a recent study published in Scientific Reports, researchers examined the relationship between cell-mediated or T lymphocyte-mediated immunity and severe acute respiratory syndrome coronavirus 2 ...
The lymphocyte-to-C-reactive protein ratio (LCR) is a new systemic immune inflammation index that might aid in the early screening and assessment of coronary artery disease (CAD) severity. Lower LCRs ...
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide ...
A $10 million pot of seed money has catapulted Ctrl Therapeutics Inc. into existence, enabling it to advance an immunotherapy approach in which tumor cells are extracted from the bloodstream rather ...
Scientists at the National Cancer Institute (NCI) report that in a clinical trial of 42 women with metastatic breast cancer, 28 (or 67 percent) generated an immune reaction against their cancer. The ...
Please provide your email address to receive an email when new articles are posted on . At baseline, patients with JIA had higher C-reactive protein and CRP-to-albumin ratio vs. controls. C-reactive ...
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors ...